| scholarly article | Q13442814 |
| P50 | author | Kishan J Patel | Q56929356 |
| David T Scadden | Q88652265 | ||
| Kenneth C. Anderson | Q28421846 | ||
| Samantha Pozzi | Q42399984 | ||
| P2093 | author name string | Mariateresa Fulciniti | |
| Teru Hideshima | |||
| Noopur Raje | |||
| Nikhil Munshi | |||
| Hua Yan | |||
| Sonia Vallet | |||
| Henry M Kronenberg | |||
| Diana Cirstea | |||
| Loredana Santo | |||
| Homare Eda | |||
| Stuart Kuhstoss | |||
| Linda Schirtzinge | |||
| P2860 | cites work | DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma | Q43247985 |
| Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment | Q43844308 | ||
| Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. | Q52919769 | ||
| Pathogenesis of myeloma bone disease. | Q55052458 | ||
| Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation | Q57904871 | ||
| The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions | Q63248240 | ||
| Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation | Q79872865 | ||
| A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma | Q24646864 | ||
| Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma | Q24669938 | ||
| Wnt signaling in B-cell neoplasia | Q28182311 | ||
| The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 | ||
| Inhibition of Wnt activity induces heart formation from posterior mesoderm | Q28346509 | ||
| Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation | Q28505419 | ||
| Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction | Q29616164 | ||
| Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma | Q34174284 | ||
| Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. | Q34346883 | ||
| Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo | Q35642745 | ||
| MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. | Q36141697 | ||
| Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo | Q36478430 | ||
| Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma | Q36547263 | ||
| Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma | Q36932713 | ||
| The role of Dickkopf-1 in bone development, homeostasis, and disease | Q37066218 | ||
| WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss | Q37073777 | ||
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma | Q37271048 | ||
| Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. | Q37484765 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| Advances in the biology and treatment of bone disease in multiple myeloma | Q37853737 | ||
| Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy | Q39692668 | ||
| Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation | Q39741986 | ||
| Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. | Q39915275 | ||
| High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties | Q39948712 | ||
| Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats | Q40277043 | ||
| Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro | Q40307786 | ||
| P433 | issue | 2 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 487-496 | |
| P577 | publication date | 2013-01-17 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma | |
| P478 | volume | 53 |
| Q38876521 | Adipose, Bone, and Myeloma: Contributions from the Microenvironment. |
| Q90570106 | Attenuation of Intestinal Epithelial Cell Migration During Cryptosporidium parvum Infection Involves Parasite Cdg7_FLc_1030 RNA-Mediated Induction and Release of Dickkopf-1 |
| Q50888455 | Bone Disease in Multiple Myeloma. |
| Q42230688 | CKAP4 is identified as a receptor for Dickkopf in cancer cells |
| Q55474543 | Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts. |
| Q91289594 | Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway |
| Q88717532 | DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone Metastasis |
| Q39044797 | DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway |
| Q34049686 | Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention |
| Q39090721 | Emerging treatment approaches for myeloma-related bone disease |
| Q35755147 | High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes |
| Q27021939 | Immunotherapy strategies for multiple myeloma: the present and the future |
| Q28975609 | Kremen1 and Dickkopf1 control cell survival in a Wnt-independent manner |
| Q38981228 | Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells |
| Q49539698 | Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
| Q36725401 | Multiple myeloma in the marrow: pathogenesis and treatments. |
| Q34038854 | Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics |
| Q57794000 | Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies |
| Q38598342 | Myeloma and Bone Disease |
| Q34025065 | Novel therapeutic targets in myeloma bone disease |
| Q38999733 | Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. |
| Q53130710 | Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis. |
| Q39345895 | Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. |
| Q40111192 | Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease |
| Q37327588 | SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. |
| Q38246639 | T cell-based targeted immunotherapies for patients with multiple myeloma |
| Q38573776 | Targeting the WNT Signaling Pathway in Cancer Therapeutics |
| Q46021160 | Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. |
| Q38128460 | Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches |
Search more.